How is the right testosterone dose decided? In a clinical practice it is decided three times, by the diagnosis, by the response and by the safety labs and it is revisited every quarter for as long as you are on therapy. In a subscription it is decided once, by a starting protocol and never revisited at all. The difference between those two answers is the difference between medicine and a funnel and this article walks through the first one in enough detail that you can hold any program to it.
- Diagnosis comes first, two morning total testosterone draws with LH and FSH, per the Endocrine Society guideline.
- The starting dose is conventional and conservative and the first adjustment waits for labs and symptoms rather than enthusiasm.
- Hematocrit, PSA and estrogen are the safety lines and each has a decision rule attached to it.
- Dose titration targets the middle of the range with symptom resolution, never the top of the range as a destination.
- The $299 flat fee means nobody here earns more when the dose changes and the pharmacy bills the medication separately at cost.
First, the diagnosis decides whether therapy starts at all
The Endocrine Society guideline is specific about what must exist before testosterone therapy begins. Consistent symptoms, unequivocally low total testosterone on two separate morning draws and a workup that includes LH and FSH to locate whether the problem is in the testes or upstream in the pituitary, with prolactin measured where indicated. That sequence is not bureaucratic caution. It exists because testosterone therapy started on one low afternoon draw and a symptom checklist treats men who never needed it and because a low LH pattern can point at the pituitary, which is a different clinical conversation entirely.
Any program that skips the second morning draw is not dosing testosterone. It is selling it. The distinction is worth naming because the second draw costs the program money and the shortcut costs the patient a decade of the wrong protocol.
The starting dose and what it is for
Where the diagnosis is confirmed, the starting dose is deliberately conservative. Standard testosterone cypionate or enanthate protocols begin in the range commonly published in clinical practice, often around 100 to 200 mg weekly or every two weeks depending on the ester and the clinician's judgment, with transdermal options where injections do not suit the patient. The starting dose is a hypothesis. Its purpose is to produce a first trough measurement and a first symptom report, not to be the final answer.
Fertility deserves its mention here rather than later. Exogenous testosterone suppresses sperm production through the same feedback loop that drives its other effects and a man who wants children in the next few years should hear that before the first injection. Alternatives exist, including clomiphene-based approaches in appropriate cases and they belong in the first conversation.
The monitoring loop
Once therapy is running, the dose is managed by a loop that repeats quarterly and each quarter reads four things.
- The trough testosterone level. Drawn mid-cycle for injectables, measured against the midpoint of the reference range. The titration target is the middle of the range with symptoms resolved, not the top of the range as a badge.
- Hematocrit. Testosterone stimulates red cell production and a hematocrit climbing past the threshold where clot risk rises triggers a dose reduction or a pause, per the guideline's monitoring section. This is the most important safety line in the entire protocol.
- PSA and the prostate conversation. Baseline PSA before starting, repeated on the audit cadence, with urology referral where the trend rather than a single value raises the question.
- Estradiol and symptoms. Aromatization varies widely between men and the estrogen line explains nipple tenderness, water retention and mood shifts that a dose-too-high picture produces. It is measured rather than guessed.
The symptom review sits alongside the labs, because the patient's report of energy, libido, sleep and mood is a clinical measurement even though no machine produces it. A dose that normalizes the trough level but leaves the symptoms untouched is not the right dose yet and a dose that fixes symptoms while pushing hematocrit to the ceiling is a dose too high.
The correct testosterone dose is the lowest one that resolves symptoms and keeps hematocrit, PSA and estradiol in their lanes. Any program that escalates toward the top of the range on purpose is dosing for a reason that is not clinical.


Why the incentive question decides the protocol
Dose titration in testosterone has the same structural conflict as it does in weight management. At programs that sell their own medication, the dose is the revenue line and higher doses of some formats carry higher margins. Our structure removes that line entirely. The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinician relationship and four Biomarker Audits a year and the medication is billed by the pharmacy separately at pharmacy cost with zero markup, no molecule upcharge and no dose escalation fee. When the protocol says hold the dose, nobody here loses income by saying it.
The membership starts with a two month commitment paid as a single $598 charge covering the first two months together and from month three it is month to month. Clinical care is delivered by licensed physicians of Beluga Health, P.A., licensed in all 50 states, working under GoodLife Health's clinical protocols.
Frequently Asked Questions
How is the right testosterone dose decided?
By a loop that runs every quarter. Diagnosis first, two morning draws with LH and FSH, then a conservative starting dose, then trough levels, hematocrit, PSA and estradiol reviewed against symptoms at each audit. The target is the middle of the range with symptoms resolved.
Why does the diagnosis need two morning draws?
Because testosterone fluctuates across the day and a single low afternoon value misdiagnoses healthy men. The Endocrine Society guideline requires two separate morning draws with consistently low results before therapy.
What is the most important safety lab on TRT?
Hematocrit. Testosterone raises red cell production and a hematocrit above the safety threshold raises clot risk and triggers a dose reduction or pause. It is checked every quarter.
Should the dose target the top of the range?
No. The titration target is the middle of the reference range with symptoms resolved. A dose pinned to the top of the range adds risk without adding benefit.
Can I stay fertile on testosterone therapy?
Exogenous testosterone suppresses sperm production. If fertility matters in the next few years, say so in the first conversation, because clomiphene-based alternatives exist and the choice should happen before the first injection.
How often should the dose be reviewed?
Every quarter, against the trough level and the safety labs. A dose that has never been revisited since it was written is a protocol that stopped being medicine.
What does this monitoring cost at GoodLife Health?
It is inside the membership. A single $598 charge covers the first two months together and from month three it is $299 monthly, month to month, cancel anytime, with four Biomarker Audits a year included. Medication is billed by the pharmacy separately at pharmacy cost with zero markup.
One last thing
Testosterone therapy is easy to start and easy to neglect. The version worth paying for is the one with a loop, a hematocrit line and a clinician who would rather lower your dose than defend it. Ask any program how often they review the dose. The answer tells you what you are buying.
Related Guides
- Hormone optimization
- Can men do hormone optimization without having low testosterone?
- What a Biomarker Audit includes
- Cardiometabolic optimization: the definitive guide
References
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism, 2018. doi.org/10.1210/jc.2018-00229
- FDA, medications containing testosterone safety communication. fda.gov
- American Urological Association, testosterone deficiency guideline. auanet.org